Cortexyme is a clinical stage pharmaceutical company developing small molecules to alter the course of Alzheimer’s and other degenerative disorders. Cortexyme is targeting a specific, undisclosed infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. The company’s lead compound, COR388, is the subject of an ongoing phase 1b clinical development program. Additional proprietary small molecules are moving forward in preclinical development.

  • Founded 2012
  • Partnered 2018
  • IPO 2019
  • Casey Lynch
  • Steve Dominy
  • MD
  • Kristen Gafric
  • JD
Sorry. This page is not yet translated.
Congratulations ThousandEyes!
  • Consumer
  • Enterprise
  • All
  • Devices
  • Financial
  • Gaming
  • Healthcare
  • Marketplace
  • Media
  • Productivity
  • Search
  • Social
  • All
  • Apps & Services
  • Data & Analytics
  • Dev Tools
  • Hardware
  • Healthcare
  • Infrastructure
  • Marketing
  • Networking
  • Security
  • Storage
The Dentmakers.

Since 1972, we have partnered early and at every stage of growth with the founders of companies that now have an aggregate, public market value of over $3.3 trillion. Meet the companies below.

Select Categories
Filter By Partner
Viewing Companies